lenalidomide has been researched along with Benign Monoclonal Gammopathies in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 10 (71.43) | 2.80 |
| Authors | Studies |
|---|---|
| Kunacheewa, C; Manasanch, EE | 2 |
| Agis, H; Eichinger-Hasenauer, S; Jeryczynski, G; Krauth, MT | 1 |
| Aouba, A; Audemard-Verger, A; Battistella, M; Bigot, A; Brihaye, B; Cook, AR; Deriaz, S; Diot, E; El Karoui, K; Ferreira-Maldent, N; Hankard, A; Henique, H; Ingen-Housz-Oro, S; Jobard, S; Lioger, B; Magnant, J; Maillot, F; Paule, R | 1 |
| Aotsuka, Y; Kano, H; Kuwabara, S; Mimura, N; Misawa, S; Morooka, M; Nakamura, K; Ohwada, C; Otani, R; Sakaida, E; Sekiguchi, Y; Shibuya, K; Suichi, T; Takeda, Y; Tsukamoto, S | 1 |
| Kumar, S; Lonial, S; Mateos, MV; Rajkumar, SV | 1 |
| Afraz, S; Cao, J; Green, A; Ibrahim, IF; Nelson, AT; Sarode, R; Shen, YP; Yates, SG | 1 |
| Bye, AP; Gibbins, JM; Grech, H; Khan, D; Kriek, N; Laffan, M; Mitchell, JL; Ramasamy, K; Rana, RH; Sage, T; Shapiro, S; Thakurta, A; Unsworth, AJ | 1 |
| Antonioli, E; Guglielmelli, P; Loscocco, GG; Mannelli, F; Romano, I; Rotunno, G; Vannucchi, AM; Vergoni, F | 1 |
| Khouri, J; Nakashima, M; Wong, S | 1 |
| Abe, N; Bohgaki, M; Kasahara, H; Koike, T; Tomita, T | 1 |
| Cameron, E; Symington, E; Thomas, W; Warner, E | 1 |
| Anderson, KC; Ghobrial, IM; Glavey, S; Görgün, GT; Kawano, Y; Manier, S; Moschetta, M; Roccaro, AM | 1 |
| Chon, SY; Silapunt, S | 1 |
5 review(s) available for lenalidomide and Benign Monoclonal Gammopathies
| Article | Year |
|---|---|
The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact.
Topics: Disease Progression; Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Quality of Life; Smoldering Multiple Myeloma | 2021 |
Smoldering multiple myeloma current treatment algorithms.
Topics: Algorithms; Biological Products; Disease Progression; Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Paraproteinemias; Smoldering Multiple Myeloma | 2022 |
High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dexamethasone; Disease Progression; Drug Administration Schedule; Early Detection of Cancer; Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Plasma Cells; Randomized Controlled Trials as Topic; Smoldering Multiple Myeloma; Survival Analysis | 2020 |
Update on the Diagnosis and Treatment of POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes) Syndrome: A Review.
Topics: Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; Paraproteinemias; POEMS Syndrome; Vascular Endothelial Growth Factor A | 2021 |
Targeting the bone marrow microenvironment in multiple myeloma.
Topics: Angiogenesis Inhibitors; Animals; Bone Marrow; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Plasma Cells; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome; Tumor Microenvironment | 2015 |
9 other study(ies) available for lenalidomide and Benign Monoclonal Gammopathies
| Article | Year |
|---|---|
Successful treatment of acquired von Willebrand syndrome associated with monoclonal gammopathy : Breaking a dangerous bond.
Topics: Cyclophosphamide; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; Paraproteinemias; Transplantation, Autologous; von Willebrand Diseases | 2022 |
IgA vasculitis with underlying monoclonal IgA gammopathy: innovative therapeutic approach targeting plasma cells. A case series.
Topics: Bortezomib; Cyclophosphamide; Dexamethasone; Humans; IgA Vasculitis; Immunoglobulin A; Lenalidomide; Melphalan; Monoclonal Gammopathy of Undetermined Significance; Paraproteinemias; Peripheral Nervous System Diseases; Plasma Cells; Prednisone; Retrospective Studies; Rituximab | 2022 |
Combined Therapy with Ixazomib, Lenalidomide, and Dexamethasone for Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome.
Topics: Boron Compounds; Dexamethasone; Endocrine System Diseases; Glycine; Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; POEMS Syndrome; Vascular Endothelial Growth Factor A | 2022 |
Successful use of lenalidomide to treat refractory acquired von Willebrand disease associated with monoclonal gammopathy.
Topics: Adult; Humans; Lenalidomide; Male; Monoclonal Gammopathy of Undetermined Significance; Paraproteinemias; von Willebrand Diseases; von Willebrand Factor | 2022 |
Multiple myeloma and its treatment contribute to increased platelet reactivity.
Topics: Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Pilot Projects; Thrombosis | 2023 |
Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bone Marrow; Calreticulin; Dexamethasone; Humans; Hydroxyurea; Lenalidomide; Male; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Osteolysis; Primary Myelofibrosis; Remission Induction; Risk Factors; Sequence Deletion; Stomatitis, Aphthous; Thrombocythemia, Essential | 2021 |
Crystalglobulinemia manifesting as chronic arthralgia and acute limb ischemia: A clinical case report.
Topics: Amputation, Surgical; Arterial Occlusive Diseases; Arthralgia; Bortezomib; Dexamethasone; Humans; Lenalidomide; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Thalidomide | 2017 |
Successful treatment of acquired von Willebrand disease with lenalidomide leading to dramatic resolution of intractable gastrointestinal bleeding: A case report.
Topics: Aged; Factor VIII; Gastrointestinal Hemorrhage; Humans; Immunoglobulin M; Lenalidomide; Male; Monoclonal Gammopathy of Undetermined Significance; von Willebrand Diseases; von Willebrand Factor | 2018 |
Generalized necrobiotic xanthogranuloma successfully treated with lenalidomide.
Topics: Aged; Aged, 80 and over; Dexamethasone; Granuloma; Humans; Lenalidomide; Male; Monoclonal Gammopathy of Undetermined Significance; Necrobiotic Disorders; Thalidomide | 2010 |